VALTURNA
LOE ApproachingNDAORALTABLET
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALTURNA is an oral fixed-dose combination tablet approved by the FDA in September 2009 for cardiovascular indications. The product is a small-molecule antihypertensive combining two distinct mechanisms of action. Specific mechanism and indication details are not available in current data.
LOE Approaching0mo to LOE
Product is in mature stage with patent expiry imminent (2026); expect organizational focus on pipeline transition and reduced headcount in brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Started May 2011
975 enrolled
HypertensionStage 2 HypertensionDiabetes
Why This Matters for Your Career
Worked on VALTURNA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.